Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022

Rhea-AI Summary

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced its participation in the 2022 American Society of Clinical Oncology (ASCO) annual meeting, set for June 3-7, 2022, in Chicago, IL. The company will present a trial-in-progress poster titled "A First-in-Human, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of Neoadjuvant Use of PH-762 Administered Intratumorally in Subjects with Advanced Melanoma". The poster's author is Professor Caroline Robert, and the presentation is scheduled for June 6, 2022, from 1:15 to 4:15 p.m. Central Time.

MARLBOROUGH, Mass., May 3, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that it will present a trial-in-progress poster at the 2022 American Society of Clinical Oncology (ASCO) annual meeting, which is being held June 3-7, 2022 in Chicago, IL. ASCO is the largest cancer meeting in the world, bringing together thousands of cancer experts from academia, industry, patient advocacy and policy.

Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg

 

Poster Details are as follows:
Title:	A First-in-Human, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of Neoadjuvant Use of PH-762 Administered Intratumorally in Subjects with Advanced Melanoma
Author:	Professor Caroline Robert, M.D., Ph.D., Head of the Dermatology Unit at Gustave Roussy and co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University
Abstract Number:	TPS9608
Session:	Melanoma/Skin Cancers
Date and Time:	June 6, 2022 at 1:15 – 4:15 p.m. Central Time

 

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor microenvironment. The Company's goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.

Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com 

Investor Contact 
Ashley R. Robinson 
LifeSci Advisors 
arr@lifesciadvisors.com 

View original content:https://www.prnewswire.com/news-releases/phio-pharmaceuticals-announces-trial-in-progress-poster-at-asco-2022-301537706.html

SOURCE Phio Pharmaceuticals Corp.

FAQ

What company is presenting at ASCO 2022?

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is presenting at ASCO 2022.

When is the ASCO 2022 meeting?

The ASCO 2022 meeting is scheduled for June 3-7, 2022.

What is the focus of Phio Pharmaceuticals' presentation at ASCO 2022?

Phio Pharmaceuticals will present a trial-in-progress poster on the safety and anti-tumor activity of PH-762 in advanced melanoma.

Who is the author of the poster being presented by Phio Pharmaceuticals?

The poster's author is Professor Caroline Robert, M.D., Ph.D.

When will Phio Pharmaceuticals present their poster at ASCO 2022?

Phio Pharmaceuticals will present their poster on June 6, 2022, from 1:15 to 4:15 p.m. Central Time.